Re-Stem Biotech Expands Cell Manufacturing and Banking Facilities to Kunming, China

 
1 2 3
Re-Stem Kunming Location
Re-Stem Kunming Location
SUZHOU, China - Aug. 22, 2019 - PRLog -- Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced the opening of their new GMP facilities in Kunming, China. Located within Yunnan Boya Private Hospital, the facilities comprise over 600 square meters, with over 200 square meters of dedicated space built and managed according to both U.S. and China GMP standards.

"We are very pleased to continue to add to our manufacturing and banking capabilities," commented Benno Jiao, CEO of the Company. "This is a key milestone to support our various stem-cell and oncology product lines and clinical studies, as it expands our research and development space, as well as our access to patients across China who are suffering from unmet medical needs."

The Company currently operates clinics and research and development labs in Suzhou, Shenzhen, Beijing, Kunming and Ganzhou, with further locations planned for Chongqing, Wuhan, and other cities across China.

About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as "will," "may," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

End
Email:***@restembiotech.com Email Verified
Tags:Re-Stem, Cancer, Laboratory
Industry:Biotech, Health
Location:suzhou - Jiangsu - China
Subject:Projects
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Aug 22, 2019



Like PRLog?
9K2K1K
Click to Share